The immunological efficacy of the combined vaccine Trimovax intended for the prevention of measles, mumps and rubella

• Published in: Žurnal mikrobiologii, ėpidemiologii i immunobiologii no. 4; p. 36
• Main Authors: Samoĭlovich, E O, Kapustik, L A, Fel'dman, E V, Ermolovich, M A, Svirchevskaia, E Iu, Titov, L P, Zakharenko, D F, Belova, E Iu, Chernovetskiĭ, M A, Korostik, T S
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) 01.07.1998
• Subjects: Antibodies, Viral - blood; Drug Evaluation; Humans; Infant; Measles - prevention & control; Measles Vaccine - adverse effects; Measles Vaccine - immunology; Measles virus - immunology; Measles-Mumps-Rubella Vaccine; Mumps - prevention & control; Mumps Vaccine - adverse effects; Mumps Vaccine - immunology; Mumps virus - immunology; Republic of Belarus; Rubella - prevention & control; Rubella Vaccine - adverse effects; Rubella Vaccine - immunology; Rubella virus - immunology; Time Factors; Urban Population; Vaccines, Combined - adverse effects; Vaccines, Combined - immunology; Republic of Belarus
• ISSN: 0372-9311

In 1996 the immunization of children against measles, mumps and rubella with combined vaccine Trimovax ("Pasteur Mérieux Connaught", France) was carried out in the Republic of Belarus. The reactogenicity of the vaccine was studied in 372 children. To evaluate immunological effectiveness, the sera of 324 children were used. Postvaccinal reactions of different intensity were registered in 5.6% of the children; of these, 1.3% exhibited severe reactions. Among the vaccinees, protective titers of antibodies to measles were found in 97.6% to mumps, in 93.8% and to rubella, in 96.0% of the children. Antibodies to all three components of the vaccine were present mainly in high and moderate titers. The results thus obtained indicate that, Trimovax was well tolerated and proved to be immunologically active.